American Society of Gene + Cell Therapy



BINERIA CAPANI, ANTINA

TUT;

autolitita

E,

o A

ווומשונת

'n

田

PRE-MEETING Workshop

NEWBORN SCREENING: TOWARD A SYSTEM THAT KEEPS PACE WITH GENE THERAPY ADVANCES MAY 15, 2022

Runtmit

11



NEWBORN SCREENING: TOWARD A SYSTEM THAT KEEPS PACE with gene therapy advances


SUNDAY, MAY 15, 2022

All times listed below ET

Co-chairs: Diane Berry, PhD, Sarepta Meagan Perry, Orchard Therapeutics

Description

This workshop will dive into the key policy issues affecting the U.S. newborn screening system, given the anticipated wave of innovative therapy approvals. Topics will include modernizing the NBS process; addressing the challenges of data collection via NBS pilot programs; and evaluating emerging screening and clinical programs.





NEWBORN SCREENIN NEWBORN SCREENING: TOWARD A SYSTEM That keeps pace with gene therapy advances

Schedule

All times listed below ET

8:00-8:55 AM

Session 1 The Recommended Uniform Screening Panel (RUSP)— Current and Future Process

Potential Solutions to Prepare Newborn Screening for Transformative Therapies Don Bailey, PhD, RTI International

Streamlining Future RUSP Applications Terri Klein, National MPS Society

Roundtable Panel: The RUSP—Current and Future Process Don Bailey, PhD, RTI International Terri Klein, National MPS Society Elisa Seeger, ALD Alliance Moderated by: Stacey Frisk, Sarepta

8:55-9:45 AM

Session 2 State Implementation and Innovation

Hastening the State Uptake of Newly Approved Conditions Erin Frey, Ultragenyx

What Can States Do Before a Condition is Added to the RUSP? Julie Morrison, Illinois State Senate

Roundtable Panel: State Implementation and Innovation

Erin Frey, Ultragenyx Annie Kennedy, EveryLife Foundation Julie Morrison, Illinois State Senate Scott Shone, PhD, North Carolina State Laboratory of Public Health Moderated by Stacey Frisk, Sarepta



NEWBORN SCREENIN NEWBORN SCREENING: TOWARD A SYSTEM THAT KEEPS PACE WITH GENE THERAPY ADVANCES

9:45–10:15 AM

Break

10:15 AM-11:05 AM

Session 3 Innovation in Clinical Trial Design for Cell and Gene Therapies: What's on the Horizon?

Opportunities of a Multi-disease Panel Approach *Melissa Wasserstein, MD, Montefiore Medical Center*

State Pilot Programs: New York's Experience Joseph Orsini, PhD, New York Department of Health



Astellas Gene Therapies is developing investigational genetic medicines for patients with rare neuromuscular disorders.

Visit our website to learn more! www.astellasgenetherapies.com

> ASTELLAS and the flying star device are registered trademarks of Astellas Pharma Inc.©2022 Audentes Therapeutics, Inc. All rights reserved

US-Corporate-032022-00001. March 2022



NEWBORN SCREENIN NEWBORN SCREENING: TOWARD A SYSTEM That keeps pace with gene therapy advances

Roundtable Panel: Data Collection and Newborn Screening Program

Amy Brower, PhD, American College of Genetics and Genomics Barbara Burton, MD, Lurie's Children's Hospital Joseph Orsini, PhD, New York Department of Health Melissa Wasserstein, MD, Montefiore Medical Center

Moderated by: Kent Christopherson, PhD, Orchard Therapeutics

11:05 AM-12:00 PM

Session 4 Evaluating Emerging Screening Methods and Clinical Programs

Evaluating Emerging Screening Methods and Clinical Programs Stephen Kingsmore, MD, DSc, Rady Children's Hospital

Evaluating Emerging Screening Methods and Clinical Programs *Richard Parad, MD, Brigham and Women's Hospital*

Roundtable Panel: Evaluating Emerging Screening Methods and Clinical Programs

Stephen Kingsmore, MD, DSc, Rady Children's Hospital Richard Parad, MD, Brigham and Women's Hospital Philip Reilly, MD, JD, Third Rock Ventures

Moderated by: Kent Christopherson, PhD, Orchard Therapeutics







25th Annual Meeting